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E  H E M O T E R A P I A
Maria de Lourdes L. F. Chauffaille Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms
(MPN), according to the 4th edition of the World Health Organization (WHO)
classification are clonal diseases of hematopoietic stem cells, in which there is increased
proliferation of the myeloid series (granulocytic, erythrocytic, megakaryocytic series
or mast cells) with effective maturation. The progression of all is characterized by
marrow fibrosis or leukemic transformation. According to the WHO classification,
the MPNs include: chronic myeloid leukemia (CML), polycythemia vera (PV), essential
thrombocythemia (ET), idiopathic myelofibrosis (IM), chronic neutrophilic leukemia
(CNL), chronic eosinophilic leukemia not otherwise categorized (CEL-NC),
mastocytosis (M) and myeloproliferative neoplasm unclassifiable (MPNU). It is worth
noting that the molecular basis of CML (BCR/ABL1), as well as PV, ET, IM (JAK2V617F
and exon 12, MPL W515L/K) and M (KITD816V) have been identified and have, in
common, constitutive activation of tyrosine kinase due to acquired hematopoietic
stem cell defects. The JAK2V617F mutation is observed in around 90% of PV cases
and in around 50-60% of IM and ET leading to the question why a single molecular
lesion induces three different clinical manifestations. There is already evidence that
additional genetic and epigenetic events contribute to the pathogenesis, including
MPL W515L/K mutation. Some clinical aspects, the pathophysiology and diagnostic
criteria of MPNs are presented in this paper. Rev. Bras. Hematol. Hemoter.
2010;32(4):308-316.
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Myeloproliferative diseases, currently called
myeloproliferative neoplasms (MPN) according to the fourth
edition of the World Health Organization (WHO)
classification, are clonal disorders of hematopoietic stem cells,
in which there is increased proliferation of the myeloid series
with effective maturation, which leads to peripheral blood
leukocytosis, increased erythrocyte mass or thrombocytosis.
Several types of MPN progress to fibrosis or leukemic
transformation.(1)
Review / Revisão
The myeloproliferative group of disorders includes the
following diseases: chronic myeloid leukemia (CML),
polycythemia vera (PV), chronic idiopathic myelofibrosis
(MF), essential thrombocythemia (ET), chronic neutrophilic
leukemia (CNL), chronic eosinophilic leukemia not otherwise
specified (CEL-NS), mastocytosis (M) and myeloproliferative
neoplasm, unclassifiable (MPNU).(1)
Some diseases, previously named CEL that present
PDGFRα, PDGFRβ and FGFR1 rearrangements are now
grouped as myeloid and lymphoid neoplasms with
eosinophilia.(1)
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Chronic myeloid leukemia
CML is a disease of mutated pluripotent hematopoietic
cells which result in the Philadelphia (Ph) chromosome.
Clinical aspects
CML has an incidence in the USA of 1.5 cases per
100,000 inhabitants per year; the median age of patients is 60
years old, but it can occur in any age group(2) with a slight
predominance of males (1.3 male: 1 female).(3) Among 240
cases of CML treated at UNIFESP between 1990 and 2000,
the median age was 43 years old.(3)
The most striking aspect of CML is leukocytosis with a
'left shift' and splenomegaly. The usual clinical manifestation
is weakness, fatigue, increased abdominal size or bloating
after meals (average size of the spleen was 5.8 cm in the
UNIFESP cases(3)) but with subsequent weight loss. These
manifestations are frequent in the chronic phase (CP) of the
disease.
The natural history of CML is an evolution, on average
over four years in the CP to blast crisis (BC). The disease is
characterized clinically by two or three phases: the first is CP,
which may be followed or not by an accelerated phase (AP)
and the acute phase or BC. In these advanced stages, the
cells do not differentiate and there is a predominance of blasts
(myeloid, lymphoid or undifferentiated). In BC, patients are
usually symptomatic with fever, bone pain, bleeding and
sweating. Tables 1 and 2 show the diagnostic criteria of AP
and BC.
BCR/ABL1 gene fusion transcribes mRNA that encodes a
protein with tyrosine kinase activity. Depending on the
breakpoint in BCR, the fusion product may be: M-BCR
(major), m-BCR (minor) or µBCR (micro). M-BCR is the
most common product in CML and results in a protein of
210 kD (p210BCR-ABL1). The m-BCR, which encodes
P190BCR-ABL1, occurs in two thirds of acute lymphoid
leukemia cases and less frequently in CML and µBCR
(p230BCR/ABL) is rarely observed.
The consequence of the BCR/ABL1 fusion protein is
cell growth and transformation independent of cytokines,
loss of apoptosis, alteration in adhesion of hematopoietic
cells to the extracellular matrix due to increased integrin activity
and genomic instability. The constitutive activity of tyrosine
kinase in the cytoplasm causes the phosphorylation of
substrates of various signal transduction cascades that affect
cell growth and differentiation.(4,5)
About 95% of CML cases have the Ph chromosome,
and the others, Ph and BCR/ABL1 negative, are classified as
a separate entity, atypical CML.(1)
Diagnostic exams
Whole blood count: CP patients usually have anemia,
leukocytosis and a normal or increased platelet count. (3)
The differential of leukocytes shows an increase in
circulating granulocytes with 'left shift' and an increased
number of basophils. In the AP, the number of blasts is
between 10% and 19%, basophilia is ≥ 20%, and platelet
count <100,000 or > 1,000,000 cells/µL. In BC, the percentage
of blasts is > 20%.
Myelogram: the CP presents with hypercellularity due
to the intense proliferation of granulocytes, resulting in a
granulocyte-erythroblast ratio of from 10 to 20:1 with
preserved maturation. The number of blasts in the CP is < 5%.
The megakaryocytic sector appears hyperplastic. There may
be eosinophilia. In the AP, the percentage of blasts is
between 10% and 19% and there may be dysplasia. In BC
there are > 20% blasts.
Karyotype: this is the best test to identify the Ph
chromosome present in 90% -95% of patients with criteria
consistent with CML. In < 5% of cases variant changes
involving two or more chromosomes in addition to the 9 and
22 chromosomes may be observed. Such situations have been
previously detailed.(6) In another < 5% of cases, additional
abnormalities may be observed such as double Ph, i(17q),
trisomy 8 and trisomy 21, among others.
Fluorescence in situ hybridization (FISH): can be
used to detect the BCR/ABL rearrangement at diagnosis
and has been recommended for situations in which there
are no metaphases for analysis or when the Ph chromosome
is absent in karyotyping. Another advantage is that FISH
can be performed using peripheral blood samples. Thanks
to the use of dual-fusion probes, several abnormal situations
Physiopathology
The pathophysiology of CML is based on the
presence of the Ph chromosome, i.e. the translocation
t(9;22)(q34;q11) or the molecular rearrangement of the BCR
and ABL1 genes, an acquired genetic abnormality. The
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with the loss of another signal or double fusion can be
detected simultaneously.(6,7) Between 9% to 33% of CML
cases have the der(9q) deletion; patients with this
characteristic have shorter expected survival than those
without such deletions. A study conducted in 120 patients
with CML Ph+/ BCR/ABL1+ treated at UNIFESP revealed
der(9q) deletion or del 5' ABL in 15% of cases. These patients
showed lower overall survival and shorter duration of
chronic phase than patients without this deletion.(7)
Bone marrow biopsy (BMB): presents hypercellular
with increased neutrophils and their precursors. The
megakaryocytes are typically smaller than normal nuclei and
hypoglobular. About 40% of patients showed increased
reticulin fibers. In the AP, prominent proliferation of small
and dysplastic megakaryocytes can be observed with an
increase in reticulin fibers. In BC, there are extensive foci of
blasts.(1)
An investigation of the BCR/ABL1 transcript by RT-
PCR is indicated at diagnosis for < 5% of cases in which the
Ph chromosome is not detected by karyotyping and, for
half of them, the BCR/ABL1 rearrangement is present.(8)
BCR/ABL1-negative cases should be investigated for other
myeloproliferative disorders. FISH and RT-PCR have also
been used in cases of fibrosis in which it is impossible to
carry out karyotyping.
The quantification of the transcript by real time PCR
is now recommended to monitor anti-tyrosinase
treatment.(9-12)
Polycythemia vera
PV is a clonal neoplastic disease characterized by
increased total erythrocyte mass regardless of the action of
usual mechanisms of erythropoiesis regulation.
Clinical aspects
PV predominantly occurs in the sixth and seventh
decades of life (0.7 to 2.5:100,000 of the population per year)
with a median survival after diagnosis of approximately 15
years.(1) It is more common in men than in women. Thrombosis
is usually the most common cause of death and, in late stage
disease, there is risk of medullary fibrosis or transformation
into acute leukemia.(1)
Symptoms include headache, plethora, tiredness,
dizziness and sweating. Itching is present in approximately
40% of patients and is attributed to increases in histamine
and the number of mast cells in the skin. Thrombotic
episodes (strokes, Budd-Chiari syndrome, myocardial
infarction, pulmonary embolism or deep vein thrombosis)
are among the most common complications, occurring in
approximately 33% of patients. Bleeding has also been
reported (25% of cases). There is an increase in the incidence
of peptic ulcers.
The disease progresses through three phases: the
prodromal or pre-polycythemia phase, in which there is only
mild or borderline erythrocytosis; plethoric phase with the
symptoms described above and the late exhaustion or
consumption stage in which there is fibrosis and complaints
that include weakness, anemia and abdominal discomfort
due to evident splenomegaly.
Physiopathology
The discovery of the acquired JAK2 V617F mutation,
which is the exchange of guanine for thymidine resulting in a
substitution of valine by phenylalanine at codon 617 of the
JAK2 gene, gave us an understanding of the pathogenesis
of this group of diseases.(13) This mutation leads to
constitutive activation of tyrosine kinase and, although this
mechanism is not completely understood, results in myeloid
cell proliferation and differentiation.(13) Other activating
mutations of JAK2 (e.g., exon 12) have also been described,
but are rarer.(13)
The JAK2 V617F mutation is observed in about 90%
of cases of PV, but also in about 50% of cases of MF and
ET.(13,14)
Diagnostic exams
According to the WHO, two major criteria and one
minor criterion or the simultaneous presence of one major
and two minor criteria are needed for the diagnosis of PV
(see Table 3): (1)
In practice, the presence of two major criteria is
sufficient in 97% of cases of PV. However, to minimize the
consequences of false-positive molecular testing, the
additional presence of at least one of three minor criteria is
required. Alternatively, the combination of the first major
criterion and two minor diagnostic criteria enables the
inclusion of rare cases of PV that can truly be negative for
known JAK2 mutations.
In addition, a high Hb/Ht ratio is required for the
diagnosis of PV, i.e. without erythrocytosis, the diagnosis
of PV is not possible.(13) Thus, the interpretation of probable
cases of PV with iron deficiency may be confusing. Iron
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replacement can not possibly be prudent, as a substantial
increase in hemoglobin may be dangerous for the
patient.(1,13) There was some controversy related to the
criteria established by the WHO, such as accepting a high
Hb/Ht ratio as a substitute for the measurement of the red
cell mass per se.(14) On applying these criteria to 77 patients
with PV and 66 with apparent erythrocytosis, Johanson et
al. detected absolute erythrocytosis in only 35% of men
and 63% of women with PV, although 14% of men and 35%
of women apparently without erythrocytosis presented it
in the analysis of the erythrocyte mass and plasma volume.(15)
So, Hb and Ht are also accepted as criteria when they reach
the 99th percentile of the normal reference value of the
specific method for age, gender and altitude of residence,
or Hb > 17 g/dL in men and > 15 g/dL in women associated
with an documented and sustained increased Hb > 2 g/dL
over the basal level for the individual that can not be
attributed to a correction of iron deficiency or a high red
cell mass > 25% than the expected mean.
The following are necessary for the diagnosis of the
post-polycythemia fibrotic phase: 1) a prior documented
diagnosis of PV according to the WHO criteria and 2) grade
2-3 (on a scale of 0-3) or 3-4 (on a scale of 0-4) fibrosis of the
bone marrow together with two of the following: 1. anemia
or sustained loss by phlebotomy or cytoreductive
medication for erythrocytosis, 2. peripheral leukoerythro-
blastosis 3. defined progressive splenomegaly both by
palpable spleen more than 5 cm from the left costal margin
or the appearance of a palpable spleen; 4. the development
of more than one of the three constitutional symptoms: loss
of > 10% weight within the previous six months, and night
sweats and fever > 37.5°C without apparent cause.
Whole blood count: shows an increased number of
blood cells, hemoglobin and hematocrit; leukocytosis may
be present with a shift to myelocytes; basophilia,
eosinophilia, and monocytosis may be seen. Platelets may
be increased in number, usually between 500,000 and
1,000,000 cells/µL.
Myelogram and BMB: usually hypercellular with
hyperplasia of all elements (even though a lack of
hypercellularity does not discard diagnosis). Atypical
megakaryocytes varying in size but with predominantly
large elements and hyperlobular nuclei are observed. There
may be a slight increase of reticular fibers but fibrosis
only occurs in cases that progress to the exhaustion stage.
Perls staining does not identify a hemosiderin deposit in
the biopsy.(16)
Karyotyping: chromosome abnormalities are seen in
from 10% to 30% of cases at diagnosis with the most common
being: +8, +9, del(20q), gain of material on 1q, del(1q) and
del(13q). With progress of the disease, the rate of
cytogenetic abnormalities are seen in somewhere around
80% of cases, especially those in the post-polycythemia
fibrotic phase and nearly 100% of cases that evolve to acute
leukemia.
Research of the JAK2 V617F mutation and others:
investigations of the V617F and JAK2 exon 12 mutations
by allele-specific PCR and sequencing are necessary to
detect other possible mutations.
Patients with idiopathic abdominal venous thrombosis
should be submitted to an investigation of the JAK2 gene
as they may progress to PV. However, the presence of the
mutation by itself in these cases does not define the case
as PV, but as an unclassified myeloproliferative disorder.(17,18)
Differential diagnosis
In secondary polycythemia (SP) there is an increase
in the number of circulating red blood cells and red cell
mass in response to stimulation of the bone marrow by
erythropoietin (Epo) or abnormal functioning of mutant
Epo receptors. Unlike PV, these patients do not show
increased leukocyte and platelet counts or splenomegaly.
SP is associated to cardiopulmonary disorders, chronic
obstructive pulmonary disease, sleep apnea syndrome,
smoker's polycythemia, polycythemia of renal tumors that
produce Epo, polycystic kidney disease, polycythemia of
high altitudes and large myomas, among other causes.
Additional studies such as blood gases, abdominal
ultrasound, polysomnography and gynecological
evaluations may be helpful in the differential
diagnosis.(19,20)
Primary myelofibrosis
Primary myelofibrosis (MF) originates from a clonal
neoplastic transformation of pluripotent hematopoietic cells
(stem cells) accompanied by intense reactive changes of
the bone marrow stroma with collagen fibrosis,
osteosclerosis and angiogenesis.
Clinical aspects
The estimated incidence is 0.5 to 1.5 cases per 100,000
inhabitants per year. A quarter of patients are asymptomatic
and the diagnosis is made by splenomegaly or by chance.
The other cases present with symptoms secondary to
anemia (weakness, fatigue, palpitations and dyspnea),
splenomegaly (satiety, discomfort or pain in the upper left
quadrant of the abdomen), hypermetabolic state (weight
loss, night sweats or fever), extramedullary erythropoiesis,
bleeding (petechiae, gastrointestinal tract bleeding), bone
changes (bone or joint pain due to osteosclerosis), portal
hypertension (ascites, esophageal or gastric varices, hepatic
encephalopathy, portal or hepatic vein thrombosis) and
immunological abnormalities (circulating immune complexes
or autoantibodies).
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The disease has two phases: the pre-fibrotic phase
starting with hypercellular bone marrow which progresses
to replace nearly all the hematopoietic tissue by reticular
fibers (the fibrotic phase). Survival varies from 3 to 10 years.
The causes of death are: leukemic transformation (5% to
10% of cases), infection, bleeding, thrombosis, heart failure,
liver failure, occurrence of another cancer, respiratory failure
and portal hypertension.(21)
Physiopathology
In MF, the fibrosis is due to clonal proliferation of
hematopoietic cells leading to hyperplasia of
megakaryocytes and monocytes that release fibrogenic
growth factor. The JAK2 V617F mutation has been
detected in approximately 50% of patients, who have high
white blood cell counts. Neutrophilia is seen in JAK2 V617F
negative individuals who have less need for transfusion
(presumably the mutation protects from severe anemia),
but clinically more aggressive disease represented by worst
survival. The JAK2 V617F is present in the homozygous
form in 13% of cases, a situation that is associated with
chromosomal abnormalities that may have an adverse
function in the biogenesis of the disease. A mutation in
the transmembrane domain of the thrombopoietin receptor
(cMPL) was observed in 9% of JAK2 V617F negative (or
MPLW515L MPLW515K) patients but also in JAK2 V617F
positive patients. So the current idea is that MPL mutations
favor the development of thrombocytosis while JAK2
V617F predisposes to erythrocytosis. However, it is hard
to blame each mutation as the sole cause of MF; perhaps
the disease is the accumulation of multiple genetic lesions
and epigenetic events.(22)
Diagnostic exams
At least three major and two minor criteria are necessary
for the diagnosis of MF.
The tests needed for diagnosis are:
Whole blood count: usually shows normochromic and
normocytic anemia (Hb < 10 g/dL in 60% of cases).
Microcytic and hypochromic anemia is also identified in
5% of cases associated to iron-deficiency. The morphology
of red blood cells shows poikilocytosis, dacryocytes and
erythroblasts in circulation. Leukopenia is present in one
quarter of the cases and leukocytosis in one third. The
leukocyte count may have a shift to younger forms, even blasts
and pseudo-Pelger-Huet anomaly. Both thrombocytosis and
thrombocytopenia may be observed with the presence of
macrothrombocytes.(23)
Myelogram and BMB: in the pre-fibrotic phase
hypercellularity can be seen with myeloid hyperplasia of
myeloid sectors. In the fibrotic phase, the aspiration is
usually dry.(1,23) Megakaryocytes are abnormal and atypical
(pleomorphic, large, but can also be small) forming clusters
adjacent to the sinuses and bone trabeculae. Reticular
fibrosis is minimal at first. In the fibrotic phase there is
reticular or collagen fibrosis. Osteosclerosis may be
present.(1,23)
Karyotyping: It may be very difficult to obtain samples
for analysis due to marrow fibrosis. Changes are evidenced
in 60% of cases with del(13q), del(20q), partial trisomy 1q,
as well as +8 and +9. This is an important examination to
differentiate between MF and CML (with the Ph
chromosome) and myelodysplastic syndrome [3q21q26 or
del(5q) abnormalities]. Cases with alterations involving
chromosome 5 or 7 are related to prior use of chemo-
therapeutic agents in the treatment of a myeloproliferative
disorder.(24)
Investigations of the JAK2 V617F mutation and others:
can be performed on peripheral blood samples by PCR
followed by sequencing or not.
Differential diagnosis
Fibrosis is a phenomenon that can occur in other
myeloproliferative diseases such as CML, ET and PV, or
even hairy cell leukemia, myelodysplastic syndrome with
fibrosis, myelodysplastic/myeloproliferative syndrome,
unclassifiable chronic myeloproliferative neoplasm, acute
megakaryocytic leukemia, acute leukemia with fibrosis and
other hematologic malignancies with no metastasis to the
bone. Clinical conditions that may present bone marrow
fibrosis as secondary events are the chronic granulomatous
diseases (tuberculosis and histoplasmosis), inflammatory
diseases, systemic lupus erythematosus, pulmonary
hypertension and diseases related to metabolism of the
parathyroid hormone (hyperparathyroidism and
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hypoparathyroidism). The clinical and laboratory aspects
are distinct from MF and should be taken into account in the
diagnosis.
Essential thrombocythemia
ET is characterized by a high platelet count with
megakaryocytic hyperplasia, although other bone marrow
sectors are affected qualitatively or quantitatively.
Clinical aspects
The incidence is 1 to 2 cases per 100,000 inhabitants/
year. The median age of patients at diagnosis is 60 years.
One-third to one-quarter of patients are symptomatic at
diagnosis and 25% to 48% have splenomegaly. Vasomotor
symptoms, characterized by headache, syncope, atypical
chest pain, sight disorders, livedo reticularis and
erythromelalgia (burning of hands or feet associated with
redness and warmth) are observed in approximately 40% of
cases.
Bleeding, thrombotic events and vascular
complications are the leading causes of morbidity and
mortality in ET. Extreme thrombocytosis is associated with
increased risk of gastrointestinal bleeding.
Hemorrhagic phenomena are observed in 26% of cases.
The majority of thrombotic events are deep vein thrombosis
and pulmonary embolism. Hepatic or portal vein thrombosis
(Budd-Chiari syndrome) occurs particularly in younger
patients.
The rates of transformation to PV, MF and AML are
2.7%, 4% and 1.4% respectively. There may also be
transformation to myelodysplastic syndrome. The
transformation to leukemia may take 1.7 to 16 years. Most
transformed patients received prior cytoreductive therapy
however transformation may also occur without treatment,
suggesting that the event is a natural sequel of the disease,
a result probably of its biology and the time from diagnosis
and not to prior therapy. In relation to post-thrombocythemia
fibrotic stage, the clinical features are identical to primary
myelofibrosis.
Physiopathology
Clonality studies show that about 55% of ET are
polyclonal (6 of 10 monoclonal and 2 of 13 polyclonal had
thrombosis, p <0.05). The relationship between
thrombocytosis and thrombopoietin (TP) is not well defined
but serum TP is normal or slightly increased. It is believed
that megakaryocytic progenitors may be hypersensitive to
TP, although there are reports of autonomous growth of
cultured megakaryocytes from patients with ET, calling into
question the involvement of pathways of intracellular signal
transduction. The acquired somatic point mutation, JAK2
V617F is present in primary cases of ET, but never observed
in cases of secondary disease.
Diagnostic tests
The four diagnostic criteria of the WHO classification
must be met for diagnosis (Table 5): (1,23,25)
The criteria for the diagnosis of post-thrombocythemia
myelofibrosis are: 1. documented prior diagnosis of ET
according to the WHO criteria; 2. grade 2-3 (on a scale of 0-3)
or 3-4 (scale of 0-4) fibrosis associated with two other criteria
of the following: 1. anemia or a decrease of > 2 g/dL of the
baseline Hb; 2. peripheral leukoerythroblastosis; 3. increased
splenomegaly defined both by an enlarged spleen palpable 5
cm beyond the left costal margin or the appearance of a
palpable spleen; 4. increased lactate dehydrogenase; and 5.
the appearance of more than one of the following
constitutional symptoms: loss of in weight > 10% in the
preceding six months or night sweats and fever without
apparent cause.
Of the available diagnostic tests, karyotyping should
always be performed to investigate the presence of the Ph
chromosome, which defines the disease as CML, thus useful
in the differential diagnosis. There are no cytogenetic
abnormalities typical of ET and the rate of alterations is
about 5%. The most frequent abnormalities identified are
trisomy 8 and 9, in addition to 13q and 20q deletions.
Abnormalities such as del(5q), t(3;3)(q21;q26,2) and
inv(3)(q21q26.2), which are associated with thrombocytosis,
are characteristics of myelodysplastic syndrome and acute
myeloid leukemia.
Differential diagnosis
Transient processes that can lead to reactive
thrombocytosis include: acute hemorrhage, recovery from
thrombocytopenia, acute inflammation, infection, response
to exercise and drug reactions. Chronic processes that also
induce thrombocytosis are: iron deficiency, hemolytic
anemia, asplenic state, chronic inflammatory disease,
chronic infectious diseases and cancer.
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Chronic neutrophilic leukemia
CNL is a rare myeloproliferative disorder characterized
by persistent peripheral neutrophilia with hypercellular
marrow and hepatosplenomegaly. (1)
Clinical aspects
The incidence and etiology are unknown. CNL affects
the elderly. Splenomegaly is an important characteristic and
the complaints usually derive from this abnormality but
hepatomegaly is also common. Mucosal or gastrointestinal
tract bleeding may be observed. The disease has a slow
progressive clinical course.(1)
Diagnostic criteria
1. leukocytosis in peripheral blood > 25,000 cells/µL,
with > 80% of the differential count composed of segmented
and band neutrophils, < 10% of immature granulocytes
(promyelocytes, myelocytes and metamyelocytes) and < 1%
myeloblasts;
2. BMB shows increased percentage and absolute
number of granulocytes, myeloblasts < 5% of nucleated bone
marrow cells, a normal pattern of maturation of neutrophils
and normal megakaryocytes or with a 'left shift';
3. hepatosplenomegaly;
4. no physiological cause for the neutrophilia (infection,
inflammation, tumors) is identified or, if present, myeloid
clonality is demonstrated by cytogenetic or molecular studies;
5. absence of the Ph or BCR/ABL1 rearrangement;
6. absence of PDGFRα, PDGFRβ and FGFR1
rearrangements;
7. no evidence of PV, MF or ET;
8. no evidence of myelodysplastic syndrome or
myelodysplastic/myeloproliferative diseases (no
granulocytic dysplasia, no myelodysplastic changes or the
other lineages and monocytes < 1000 cells/µL).
Diagnostic tests
Whole blood count: shows leukocytosis (> 25,000
cells/µL), with a predominance of segmented and band
neutrophils, immature granulocytes make up < 10% of the
cells and myeloblasts < 1%.
Myelogram and BMB: hypercellular with increased
granulocytes, blasts < 5% and normal pattern of maturation.
Mild fibrosis is occasionally observed. (1)
Karyotyping: is normal in most cases. The Ph
chromosome can not be present. Rare cases may show
abnormalities common to other MPNs such as +8, +9, del(20q)
and del(11q). (1)
Chronic eosinophilic leukemia, not otherwise
specified
In CEL, there is an autonomous and clonal proliferation
of eosinophilic precursors, resulting in persistent
myeloproliferation in bone marrow, peripheral blood and
tissues. Organ damage occurs as a result of leukemic
infiltration or the release of cytokines, enzymes and other
proteins by eosinophils. (1)
Patients with CML BCR/ABL1+ are excluded from this
category as are patients with PDGFRα, PDGFRβ and FGFR1
rearrangements.
CEL is more common in men at a ratio of 9:1 woman with
the peak incidence being between 20 and 50 years old. Rare
cases have been observed in infants and children.(26)
The diagnostic criteria for CEL are: (1)
1. eosinophils > 1500 cells/µL in peripheral blood;
2. absence of the Ph chromosome or other BCR/ABL1+
MPN (PV, ET and MF) and myelodysplastic/myelo-
proliferative disorders;
3. absence of t(5;12)(q31-35,p13) or other PDGFRβ
rearrangements;
4. absence of FIP1L1/PDGFRα or other PDGFRα
rearrangements;
5. absence of the FGFR1 rearrangement;
6. the blast count in peripheral blood and bone marrow
is < 20% and there is no inv(16)(p13;q22) or t(16;16)(p13;q22)
or other diagnostic characteristics of AML;
7. there are molecular or cytogenetic clonal
abnormalities or blasts > 2% in the peripheral blood or > 5%
in bone marrow.
Clinical aspects
About 10% of patients are diagnosed by chance
because they are asymptomatic. In other cases, symptoms
such as fever, fatigue, cough, angioedema, muscle pains, rash
and diarrhea are common.(1) Anemia, thrombocytopenia,
mucosal ulceration, endomyocardial fibrosis and
splenomegaly are also common.
The most important clinical finding is related to
endomyocardial fibrosis with restrictive heart disease, which
is irreversible. Heart disease triggered by the infiltration of
eosinophils in the endocardium has a necrotic initial stage
lasting an average of five weeks. In this stage, the disease
is not clinically recognized and generally goes unnoticed in
echocardiography and angiography as ventricular wall
thickening has not occurred. Sometimes, just a right
ventricular endomyocardial biopsy allows diagnosis at this
stage. In the second 'thrombotic' stage, with an average
duration of ten months, there is mural thrombus formation
with the potential of embolization to the brain. Finally, in
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the fibrotic third stage after two years, endomyocardial
fibrosis occurs that results in mitral and/or tricuspid valve
regurgitation when valve replacement may be necessary. The
clinical presentation includes dyspnea, chest pain, congestive
heart failure and cardiomegaly, as well as T-wave inversion
on electrocardiograms.
Peripheral neuropathy, central nervous system
dysfunction and pulmonary symptoms may also be present.(1)
Diagnostic tests
The investigation of a patient with hypereosinophilia
should follow a logical line of reasoning to discard causes
of reactive eosinophilia and MPN with rearrangements as
described above, as well as identifying clonality in
eosinophils (a phenomenon that is difficult to prove) or an
increase in blasts in the peripheral blood or bone marrow.
Whole blood count: eosinophilia persistently > 1500
cells/µL. Eosinophils in LEC are usually mature cells, with
smaller numbers of interspersed myelocytes and
promyelocytes. There is morphological heterogeneity, with
sparse granulation and light areas in the cytoplasm,
cytoplasmic vacuolization, nuclear hyper or hypo-
segmentation and an increased size, but these changes are
indistinguishable between reactive and neoplastic cases.
There are < 20% blasts.
Myelogram and BMB: The marrow is hypercellular due
to eosinophil proliferation; erythropoiesis and
megakaryocytopoiesis are usually normal but fibrosis can be
observed in some cases.
Karyotyping: this must be performed systematically in
bone marrow samples because it can detect clonal
abnormalities observed in this disease or other abnormalities
that lead to a correct diagnosis, for example, the presence of
the Ph chromosome, which indicates LMC; t(5,12) which
demonstrates chronic myelomonocytic leukemia with
eosinophilia, etc..
FISH and RT-PCR: These tests can detect FIP1L1/
PDGFRa, PDGFRß and FGFR1 rearrangements, which define
these cases as other subtypes as will be discussed later.
Differential diagnosis
A significant (> 5%) and sustained increase in
circulating eosinophils is usually due to parasitic
(eosinophilia severe), allergic (eosinophilic mild to moderate)
or inflammatory diseases or rarer clonal or idiopathic
situations, which present with severe tissue damage as a
result of eosinophilic infiltration. (27,28)
CEL-NS can be distinguished from other clonal
hematopoietic diseases in which eosinophilia is part of the
neoplastic clone, such as CML, PV, ET, MF, myelodysplastic
syndromes, AML [myelomonocytic with inv(16) or CBFß/
MYH11 rearrangement with maturation t(8;21) or the ETO/
AML1 rearrangement].(1) CEL-NS must also be differentiated
from myeloid and lymphoid proliferations with eosinophilia
with the FIP1L1/PDGFRα , PDGFRβ and FGFR1
rearrangements and should be distinguished from situations
that occur with aberrant phenotypes of clonal T cell
populations and abnormal cytokine or G-CSF
production.(1,29)
Once clonal and reactive causes for hypereosinophilia
have been discarded, there is still the poorly understood
idiopathic hypereosinophilic syndrome (HES) to be
considered.(1)
HES is a heterogeneous group of diseases
characterized by eosinophilia in the peripheral blood or
tissue, resulting in end organ damage. But the differentiation
between HES and CEL is that there is no proven clonality
and no increase in blasts. For the diagnosis of HES, the
following criteria must be met: 1. eosinophils > 1500 cells/
mL in peripheral blood for more than six months 2. reactive
causes discarded, lack of clonality, 3. AML, MPN, SMD,
SMD/MP discarded 4. absence of an immunophenotypically
anomalous T cell population or production of
cytokines.(1,30,31) 5. evidence of organ damage caused by
eosinophilia.
Therefore, a disease is only defined as HES when
criteria 1 to 4 are present, however, if there is no tissue
injury it is still idiopathic hypereosinophilic syndrome.
The clinical presentation is highly variable, with
patients totally asymptomatic and requiring no treatment and
with long survival, while others have rapidly progressive
and fatal disease, such as congestive heart failure or leukemic
transformation.
The main target organs are the skin, heart and central
nervous system with more than 50% of patients presenting
clinical complications in each of these structures. Eosinophil
infiltration of the lung, liver, spleen, digestive system, joints
and kidneys occurs with variable frequency, but any organ
or system can be involved.
Resumo
As síndromes mieloproliferativas crônicas, atualmente denominadas
neoplasias mieloproliferativas (NMP), de acordo com a 4ª. edição
da classificação da Organização Mundial da Saúde (OMS), são
doenças clonais de célula-tronco hematopoética, nas quais há a
proliferação aumentada de uma ou mais das séries mieloides
(granulocítica, eritrocítica, megacariocítica ou mastocítica) com
maturação eficaz. A progressão de todas é caracterizada por fibrose
medular ou transformação leucêmica. Pela classificação da OMS,
as NMP incluem: leucemia mieloide crônica (LMC), policitemia
vera (PV), mielofibrose idiopática crônica (MF), trombocitemia
essencial (TE), leucemia neutrofílica crônica (LNC), leucemia
eosinofílica crônica não especificada (LEC), mastocitose (M) e
neoplasia mieloproliferativa inclassificável (NMI). É interessante
notar que tanto a LMC (BCR/ABL1) como PV, MF e TE (JAK2
V617F e éxon 12, MPLW515L/K) e M (KITD816V) tiveram suas
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bases moleculares desvendadas e apresentam em comum a ativação
constitutiva de tirosino-quinase graças às mutações adquiridas pela
célula-tronco hematopoética. A mutação JAK2 V617F é observada
em mais de 90% dos casos de PV, mas também em cerca de 50%-
60% das MF e TE, levando ao questionamento de como uma única
lesão molecular desencadeia três manifestações clínicas diversas.
Já há evidências de que eventos genéticos e epigenéticos adicionais
contribuem para a patogênese, tais como MPLW515L e MPLW515K.
No presente manuscrito são apresentados os aspectos clínicos, a
fisiopatologia e os critérios diagnósticos das diferentes NMP. Rev.
Bras. Hematol. Hemoter. 2010;32(4):308-316.
Palavrs-chave: Transtornos mieloproliferativos; leucemia mieloide
crônica; policitemia vera; trombocitemia essencial; mielofibrose
primária; mutação.
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